Johnson & Johnson $JNJ Shares Bought by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System increased its position in Johnson & Johnson (NYSE:JNJ) by 2.7% during the third quarter, HoldingsChannel.com reports. The fund owned 119,924 shares of the company’s stock after acquiring an additional 3,108 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Johnson & Johnson were worth $22,236,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Emerald Advisors LLC increased its position in shares of Johnson & Johnson by 4.6% in the third quarter. Emerald Advisors LLC now owns 3,514 shares of the company’s stock valued at $652,000 after buying an additional 154 shares in the last quarter. Dupree Financial Group LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $212,000. Occidental Asset Management LLC increased its holdings in Johnson & Johnson by 29.4% during the 3rd quarter. Occidental Asset Management LLC now owns 5,164 shares of the company’s stock valued at $958,000 after acquiring an additional 1,172 shares in the last quarter. Gold Investment Management Ltd. raised its position in Johnson & Johnson by 2.2% during the third quarter. Gold Investment Management Ltd. now owns 19,212 shares of the company’s stock worth $3,562,000 after acquiring an additional 422 shares during the last quarter. Finally, Howland Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 6.6% in the third quarter. Howland Capital Management LLC now owns 74,668 shares of the company’s stock valued at $13,845,000 after purchasing an additional 4,616 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $218.09 on Wednesday. The company has a market cap of $525.43 billion, a P/E ratio of 21.05, a P/E/G ratio of 2.25 and a beta of 0.34. The business has a fifty day simple moving average of $206.92 and a 200-day simple moving average of $188.05. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $220.11. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on JNJ. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research note on Monday, October 20th. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Wolfe Research upped their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research report on Monday, January 5th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Finally, Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $213.33.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive Phase 3 results for CAPLYTA (major psychiatric drug) showed stronger remission outcomes, lifting biotech/pharma sentiment around JNJ. CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says
• Positive Sentiment: Robotic surgery business and a recent regulatory submission are cited as supporting JNJ’s dividend-growth outlook, reinforcing income-investor interest. Robotic surgery fuels Johnson & Johnson dividend growth outlook
• Positive Sentiment: High-profile bullish coverage: Jim Cramer has been increasingly positive on JNJ, noting strength in the cancer portfolio and framing JNJ as a core holding — a boost to retail sentiment. Jim Cramer Says He Was Wrong for Selling Johnson & Johnson for the Charitable Trust
• Positive Sentiment: Market commentary points to JNJ nearing a 52-week high as CAPLYTA data and earnings momentum lift near-term upside expectations. Johnson & Johnson Near 52-Week High As CAPLYTA Data Boosts Sentiment
• Neutral Sentiment: Analyst previews ahead of Q4 (earnings due Jan 21) are broadly constructive — core pharma and MedTech strength cited, but Q4/2026 guidance is the key near-term catalyst. Johnson & Johnson Q4 preview: Strength in core portfolio keeps analysts bullish
• Neutral Sentiment: Coverage pieces detail ways to generate income from JNJ shares and options ahead of earnings — increased retail/options activity could amplify intraday moves. How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings
• Neutral Sentiment: Index/sector coverage notes JNJ’s MedTech reach on Dow-related indices — supportive for passive flows but not an immediate price catalyst. Johnson & Johnson (NYSE:JNJ) Dow Jones Index Medical Technology Reach
• Negative Sentiment: Broader market “risk-off” (Davos/Trump headlines) pressured US equities today, which weighed on JNJ despite company-specific gains. Markets Switch to “Risk-Off” Ahead of Trump at Davos
• Negative Sentiment: Analysts and previews flag near-term risks: Stelara biosimilar competition and China headwinds could pressure growth and margin recovery in 2026. Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?
• Negative Sentiment: Outlook risk: commentary warns 2026 guidance will be a big test for JNJ’s valuation — missed targets or cautious guidance could trigger a pullback. Johnson & Johnson’s $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.